Puma Biotechnology, Inc.
A biopharmaceutical company based in Los Angeles that develops and sells cancer treatments, best known for its breast-cancer drug Nerlynx, a pill given to adults with HER2-positive breast cancer to help stop the disease from returning. It was founded in 2010 by Alan Auerbach, the same entrepreneur behind the earlier Cougar Biotechnology, whose big-cat naming theme it kept: puma and cougar are simply two names for the same mountain lion, and the drug itself was licensed from Pfizer in 2011.
Sold 1.99M
Granted 3.78M · Sold 477.7K
Bought 2.49M
Granted 51.0K
Granted 343.4K · Sold 103.4K
Granted 288.1K · Sold 81.1K
Granted 217.1K · Sold 60.3K
Granted 126.6K · Bought 30.0K
Granted 146.8K · Sold 23.8K
Granted 184.5K · Bought 30 · Sold 62.9K
Granted 162.9K · Sold 49.0K
Granted 135.0K · Sold 44.2K
Granted 213.5K · Sold 132.5K
Granted 108.0K · Sold 39.1K
Granted 213.9K · Sold 154.5K
Granted 213.9K · Sold 155.5K
Granted 53.6K · Sold 12.9K
Granted 40.5K · Sold 8.5K
Granted 213.9K · Sold 186.9K
Granted 31.5K · Sold 5.2K
Granted 25.7K
Granted 31.5K · Sold 11.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Atchinson Robert +4 co-filers10% owner · 30 transactions | — | 7.95Mas of Jun 2017 | — | — | 1.99M |
| Auerbach Alan HPresident and CEO, Director, 10% owner · 83 transactions | — | 7.31M | 3.78M | — | 477.7K |
| Adage Capital Partners GP LLC +4 co-filers10% owner · 26 transactions | — | 5.69Mas of Nov 2013 | — | 2.49M | — |
| Zavrl FrankDirector · 3 transactions | — | 960.1Kas of Jun 2020 | 51.0K | — | — |
| Nougues Maximo FChief Financial Officer · 41 transactions | — | 240.0K | 343.4K | — | 103.4K |
| Hunt Douglas MSee Remarks · 47 transactions | — | 205.3K | 288.1K | — | 81.1K |
| Ludwig Jeffrey JeromeChief Commercial Officer · 13 transactions | — | 156.8Kas of Feb 2025 | 217.1K | — | 60.3K |
| Malley ThomasDirector · 5 transactions | — | 156.6Kas of Oct 2012 | 126.6K | 30.0K | — |
| Wong Alvin FChief Scientific Officer · 12 transactions | — | 141.2Kas of Feb 2024 | 146.8K | — | 23.8K |
| Bryce Richard PaulSEE REMARKS · 53 transactions | — | 121.7Kas of Apr 2021 | 184.5K | 30 | 62.9K |
| Stuglik Brian MDirector · 11 transactions | — | 113.9K | 162.9K | — | 49.0K |
| Dorval AllisonDirector · 9 transactions | — | 90.8K | 135.0K | — | 44.2K |
| Miller Michael PatrickDirector · 15 transactions | — | 81.0K | 213.5K | — | 132.5K |
| Cesano AlessandraDirector · 6 transactions | — | 68.8K | 108.0K | — | 39.1K |
| Wilson Troy EdwardDirector · 16 transactions | — | 60.3K | 213.9K | — | 154.5K |
| Moyes Jay MDirector · 17 transactions | — | 58.3K | 213.9K | — | 155.5K |
| Miller Ann CalbyDirector · 3 transactions | — | 40.7Kas of Jun 2021 | 53.6K | — | 12.9K |
| Eyler Charles RSEE REMARKS · 13 transactions | — | 32.0Kas of Feb 2019 | 40.5K | — | 8.5K |
| Senderowicz AdrianDirector · 16 transactions | — | 27.0K | 213.9K | — | 186.9K |
| Charnas RobertSee Remarks · 4 transactions | — | 26.5Kas of Feb 2017 | 31.5K | — | 5.2K |
| O'Dowd HughDirector · 1 transaction | — | 25.7Kas of Jun 2020 | 25.7K | — | — |
| Lo StevenChief Commercial Officer · 7 transactions | — | 19.6Kas of Jul 2019 | 31.5K | — | 11.9K |
| Johnson Robert AndrewFormer President and Director · 1 transaction | — | 0as of Oct 2011 | — | — | — |
| Munjal KapilFormer Director · 1 transaction | — | 0as of Oct 2011 | — | — | — |
| Siddiqi FaraazFormer Secretary and Director · 1 transaction | — | 0as of Oct 2011 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -1.08M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.